You are here: Home > Prescription(RX) Drugs > B > Branchamin (Baxter Healthcare Corporation)|
valine injection, solution
4% BranchAmin® (Branched Chain Amino Acid)
|Total Nitrogen||443 mg|
|pH||6.0 (5.0 to 7.0)|
|Osmolarity (calc.)||316 mOsmol/L|
4% BranchAmin® (Branched Chain Amino Acid) Injection, when appropriately admixed with a complete amino acid injection, such as Travasol® (Amino Acid) Injection, with or without a concentrated calorie source, provides total parenteral nutrition for the severely compromised patient. A common effect of severe stress conditions is depletion of branched chain amino acids. Enriching the standard amino acid solution in TPN with additional branched chain amino acid results in their repletion.
See package insert of the complete amino acid solution for additional information such as Contraindications, Warnings and Precautions pertinent to that drug and general total parenteral nutrition therapy.
4% BranchAmin® (Branched Chain Amino Acid) Injection, when appropriately admixed with a complete amino acid injection such as Travasol® Injection, is indicated as an adjunct in offsetting of nitrogen loss or in the treatment of negative nitrogen balance in patients where (1) the alimentary tract cannot or should not he used; (2) gastrointestinal absorption of protein is impaired; or (3) nitrogen homeostasis is substantially impaired as with severe trauma or sepsis. Dosage, route of administration and concomitant infusion of nonprotein calories are dependent on various factors such as nutritional and metabolic status of the patient, anticipated duration of parenteral nutritional support and vein tolerance. See Dosage and Administration for additional information.
Central venous infusion should be considered when amino acid solutions are to be admixed with hypertonic dextrose to promote protein synthesis such as for hypercatabolic or depleted patients or those requiring long-term parenteral nutrition.
For patients in whom the central venous route is not indicated, amino acid solutions mixed with low dextrose concentrations may be infused by peripheral vein when supplemented with or without fat emulsion.
Enrichment of the TPN solution with the branched chain amino acid additive is recommended until the patient exhibits a marked reduction in the clinical signs and symptoms of metabolic stress, usually 7 to 14 days.
4% BranchAmin® (Branched Chain Amino Acid) Injection should not be administered to patients with inborn errors of metabolism, especially those involving branched chain amino acids such as maple syrup urine disease, isovaleric acidemia, etc.
Supplementation of branched chain amino acids should occur only with concomitant administration of solutions having complete amino acid profiles and energy substrates designed to meet minimal protein and calorie requirements.
WARNING: This product contains aluminum that may be toxic. Aluminum may reach toxic levels with prolonged parenteral administration if kidney function is impaired. Premature neonates are particularly at risk because their kidneys are immature, and they require large amounts of calcium and phosphate solutions, which contain aluminum.
Research indicates that patients with impaired kidney function, including premature neonates, who receive parenteral levels of aluminum at greater than 4 to 5 µg/kg/day accumulate aluminum at levels associated with central nervous system and bone toxicity. Tissue loading may occur at even lower rates of administration.
The concentration of 4% BranchAmin® (Branched Chain Amino Acid) Injection is close to the solubility limits of the components. If exposed to cold, crystals may form. Redissolve any formed crystals by warming to 50ºC. Note: Protect closure from contamination. Do not admix until solution is clear and free of visible particulates.
Animal reproduction studies have not been conducted with 4% BranchAmin® (Branched Chain Amino Acid) Injection. It is also not known whether 4% BranchAmin® (Branched Chain Amino Acid) Injection can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. 4% BranchAmin® (Branched Chain Amino Acid) Injection should be given to a pregnant woman only if clearly needed.
It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when 4% BranchAmin® (Branched Chain Amino Acid) Injection is administered to a nursing mother.
Clinical studies of 4% BranchAmin® (Branched Chain Amino Acid) Injection did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from other younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or drug therapy.
Clinical studies have shown that stressed patients can safely utilize up to 1.4 g/kg/day of a 50% branched chain amino acid supplemented solution. However, the total daily dose of the branched chain amino acid supplemented solutions depends upon the judgement of the physician based upon the patient's metabolic requirement, branched chain amino acid deficits and clinical response.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit. Use of a final filter is recommended during administration of all parenteral solutions where possible.
Care should be exercised to insure the maintenance of proper levels of serum potassium. Quantities of 60 to 180 mEq of potassium per day have been used with adequate clinical effect. All serum electrolytes should be monitored frequently and electrolyte requirements individualized.
Usual administration of 4% BranchAmin® (Branched Chain Amino Acid) Injection is as a supplement to parenteral nutrition solutions to achieve an amino acid solution which is approximately 50% w/w branched chain amino acid. (One method for achieving this ratio is the admixture of two volumes of 4% BranchAmin® (Branched Chain Amino Acid) Injection at 4 g/100 mL concentration with one volume of an amino acid solution of 8 to 10 g/100 mL concentration.) The supplemental amino acid mixture is administered in combination with energy substrates to provide at least 35 kcal/kg ideal body weight as nonprotein calories.
4% BranchAmin® (Branched Chain Amino Acid) Injection in the Pharmacy Bulk Package is intended for use in the preparation of sterile, intravenous admixtures. Additives may be incompatible with the fluid withdrawn from this container. Complete information is not available. Those additives known to be incompatible should not be used. Consult with pharmacist, if available. When compounding admixtures, use aseptic technique. Mix thoroughly. Do not store any unused portion of 4% BranchAmin® (Branched Chain Amino Acid) Injection.
Tear overpouch down side at slit and remove solution container. Some opacity of the plastic due to moisture absorption during the sterilization process may be observed. This is normal and does not affect the solution quality or safety. The opacity will diminish gradually. Check for minute leaks by squeezing inner bag firmly. If leaks are found, discard solution as sterility may be impaired.
Exposure of pharmaceutical products to heat should be minimized. Avoid excessive heat. Protect from excessive cold or freezing. It is recommended the product be stored at room temperature (25ºC/77ºF).
leucine, isoleucine and valine injection, solution
Revised: 12/2005 Baxter Healthcare Corporation
Reproduced with permission of U.S. National Library of Medicine
Copyright © 2018
|Over-the-counter (OTC) Drugs|